For Q2 FY2026 ended June 30, 2026, NovoCure reported revenue of $183.6 million, up 15.6% year-over-year. Net loss narrowed to $15.7 million from $40.2 million a year ago, a 61.0% improvement. Operating loss improved 73.3% to $10.6 million. Diluted EPS was -$0.13, compared to -$0.36 in the prior year. The company had $93.7 million in cash, $338.1 million in equity, and $195.0 million in long-term debt.
•Revenue grew 15.6% YoY to $183.6 million.
•Net loss improved 61.0% to $15.7 million.
•Operating loss improved 73.3% to $10.6 million.
•Diluted EPS was -$0.13, up from -$0.36.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
NovoCure Limited, an oncology company provides the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers globally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Incorporated in 2000, NovoCure is headquartered in Baar, Switzerland.
NovoCure Limited is an oncology company focused on developing, manufacturing, and commercializing tumor treating fields (TTFields) devices for the treatment of solid tumor cancers globally. Its main products include Optune Gio, Optune Lua, and Optune Pax, which are non-invasive devices that deliver electric fields to disrupt cancer cell division. The company is also conducting clinical trials investigating TTFields in various cancers such as brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure's technology represents a novel approach to cancer treatment, offering an alternative or complementary therapy to traditional methods like chemotherapy and radiation.
Where is NovoCure (NVCR) listed and what currency is used?
NovoCure Limited is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol NVCR. The company's shares are traded in US Dollars (USD). As a foreign private issuer incorporated in Switzerland, NovoCure's listing on a major US exchange provides investors with access to its stock in the world's largest capital market. The use of USD facilitates trading for international investors and aligns with the company's global operations, as it generates revenue in multiple currencies but reports its financial results in US dollars.
What sector and industry does NovoCure (NVCR) operate in?
NovoCure operates in the Healthcare sector, specifically within the Medical Devices industry. The company develops and commercializes innovative medical devices that use tumor treating fields (TTFields) to treat solid tumor cancers. Unlike pharmaceutical companies that develop drugs, NovoCure's products are non-invasive devices that are worn by patients and deliver low-intensity electric fields to disrupt cancer cell division. This places the company at the intersection of oncology and medical technology, focusing on device-based therapies rather than chemical or biological treatments. The Medical Devices industry includes companies that produce equipment, instruments, and implants used in healthcare, and NovoCure's TTFields technology is a unique niche within this space.
Where is NovoCure (NVCR) headquartered and what markets does it serve?
NovoCure Limited is headquartered in Baar, Switzerland, and was incorporated in 2000. The company operates globally, with a presence in major markets including the United States, Europe, and Asia. Its products are approved and commercialized in multiple countries for the treatment of certain cancers, such as glioblastoma. NovoCure's global operations are supported by manufacturing facilities and research centers in various locations. The company's Swiss headquarters oversees its worldwide activities, including clinical trials, regulatory approvals, and commercial sales. By serving patients across different regions, NovoCure aims to expand access to its innovative TTFields therapy for solid tumor cancers.
How does NovoCure (NVCR) generate revenue?
NovoCure generates revenue primarily through the sale and rental of its tumor treating fields (TTFields) devices, including Optune Gio, Optune Lua, and Optune Pax. These devices are prescribed by physicians for the treatment of solid tumor cancers, and patients typically use them over an extended period. The company earns recurring revenue from device rentals and disposables, such as transducer arrays that need to be replaced regularly. Additionally, NovoCure receives revenue from international sales and licensing agreements. The company's business model focuses on providing a continuous therapy, which creates a steady stream of income from each patient. Ongoing clinical trials and potential new indications for TTFields could expand its revenue base in the future.